253 related articles for article (PubMed ID: 16080485)
1. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.
Gadducci A; Gargini A; Palla E; Fanucchi A; Genazzani AR
Anticancer Res; 2005; 25(3c):2509-13. PubMed ID: 16080485
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
Sharma S; Rezai K; Driscoll D; Odunsi K; Lele S
Gynecol Oncol; 2006 Oct; 103(1):181-5. PubMed ID: 16574203
[TBL] [Abstract][Full Text] [Related]
3. A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Carter J; Durfee J
Gynecol Oncol; 2007 Dec; 107(3):586-9. PubMed ID: 17949798
[TBL] [Abstract][Full Text] [Related]
4. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
5. Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF).
Vlasveld LT; Ten Bokkel Huinink WW; Rodenhuis S
Neth J Med; 1990 Oct; 37(3-4):158-61. PubMed ID: 2250761
[TBL] [Abstract][Full Text] [Related]
6. Neutropenic enterocolitis in breast cancer patient after taxane-containing chemotherapy.
Oehadian A; Fadjari TH
Acta Med Indones; 2008 Jan; 40(1):29-33. PubMed ID: 18326897
[TBL] [Abstract][Full Text] [Related]
7. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
8. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
9. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Misawa A; Yasuda M
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
11. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Bolis G; Scarfone G; Villa A; Parazzini F
Gynecol Oncol; 2001 May; 81(2):331-3. PubMed ID: 11330974
[No Abstract] [Full Text] [Related]
13. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
16. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
17. Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.
Argon A; Aydiner A; Tas F; Saip P; Topuz E
Gynecol Oncol; 2002 May; 85(2):362-4. PubMed ID: 11972401
[TBL] [Abstract][Full Text] [Related]
18. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
